Did you know?

Buy biotech stock Geron for a 70% return in 12 months: Goldman Sachs. Sell-off in Geron Corp (NASDAQ: GERN) over the past three months has created a great buying opportunity, says Corinne Jenkins – a Goldman Sachs analyst. Geron shares could shoot up to $4.0 Jenkins upg... 2 months ago - Invezz.Feb 23, 2022 · GERN has a market cap of $334mn and a cash reserve of $215mn. Research and development expenses for the three months ended September 30, 2021 were $18.5 million, while general and administrative ... Feb 2, 2023 · GERN - Free Report) closed at $3.34 in the latest trading session, marking a -1.18% move from the prior day. This move lagged the S&P 500's daily gain of 1.47%. Elsewhere, the Dow lost 0.11% ... Stock Price Statistics The stock price has decreased by -16.81% in the last 52 weeks. The beta is 0.82, so Geron's price volatility has been lower than the market average.Upon the distributions of the Series A common stock to Geron’s stockholders described above, BioTime will own approximately 71.6%, Geron stockholders will own approximately 21.4%, and Romulus ...Since its IPO on the Shenzhen stock exchange, its share price has gone up every day by the exact same amount. Baofeng Technologies is China’s best performing stock this year. Since its IPO on the Shenzhen stock exchange, its share price has...Stock Price Forecast. According to 4 stock analysts, the average 12-month stock price forecast for Geron stock is $4.75, which predicts an increase of 141.12%. The lowest target is $4.00 and the highest is $6.00. On …4 jan. 2023 ... ... stock in an underwritten public offering. All of the securities in the proposed offering are to be sold by Geron. Geron intends to grant the ...With its Q1 2023 financials, Geron (GERN) announced Thursday it is preparing for a potential commercial launch of its blood cancer therapy imetelstat. Read more here.Get Our Latest Research Report on Geron. Geron Trading Up 3.1 %. Shares of Geron stock opened at $1.99 on Friday. Geron Co. has a twelve month low of $1.68 and a twelve month high of $3.84.Dec 1, 2023 · Geron has generated ($0.34) earnings per share over the last year ( ($0.34) diluted earnings per share). Earnings for Geron are expected to grow in the coming year, from ($0.35) to ($0.31) per share. Geron has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 21st, 2024 based ... One thing seems almost assured: Geron stock will continue to be volatile. While shares of the biotech soared on Friday following J&J's new job posting, Geron gave back some of those gains on Monday.il y a 10 heures ... This means that the stock's trading pattern over the last month have been neutral. Geron Corp currently has the 131th highest Short-Term ...FOSTER CITY, Calif., June 20, 2023--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the submission to the United States Food and Drug ...Geron Corporation ( NASDAQ: GERN) added ~9% on Tuesday in the morning hours after Goldman Sachs upgraded the biotech to Buy from Neutral, citing a potential FDA approval for its blood cancer ...Dec 1, 2023 · 6.0%. 10% most volatile stocks in US Market. 15.3%. 10% least volatile stocks in US Market. 2.9%. Stable Share Price: GERN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week. Volatility Over Time: GERN's weekly volatility (8%) has been stable over the past year. Geron Corp. (NASDAQ: GERN)’s stock price has gone decline by -4.52 in comparison to its previous close of 1.99, however, the company has experienced a -0.52% decrease in its stock price over the last five trading days. Business Wire reported 2023-11-07 that FOSTER CITY, Calif.–(BUSINESS WIRE)–Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today […]What is Geron's consensus rating and price target? According to the issued ratings of 3 analysts in the last year, the consensus rating for Geron stock is Buy based on the current 3 buy ratings for GERN. The average twelve-month price prediction for Geron is $4.75 with a high price target of $6.00 and a low price target of $4.00.Dividends on Geron stock: dividend pay date calendar, dividend per share, dividend payment, dividend historical data, dividend policy, dividend news, dividend schedulet, dividend chart. ... Geron Corporation, a late-stage clinical biopharmaceutical company, ...Geron shareholders would also receive BioTime stock-purchase warrants presently valued at approximately $13 million. Geron would retain its cancer therapy business, including Imetelstat and GRN1005, and its cash and short-term liquid investments and Geron shareholders would continue to own 100% of the Geron cancer therapy business …On April 23, 2020, plaintiff Katharine Jameson filed a verified stockholder derivative complaint in the United States District Court for the Northern District of California (the “Jameson Action”) against certain current and/or former directors and officers of Geron alleging breaches of fiduciary duty, unjust enrichment, and violations of ...NVIDIA Corporation Common Stock. $426.835 +2.705 0.64%. MULN. Mullen Automotive, Inc. Common Stock. $0.1588 +0.0579 57.38%. Find the latest on short interest for Geron Corporation Common Stock ...Geron stock has received a consensus rating of buy. The average rating score is and is based on 14 buy ratings, 1 hold ratings, and 0 sell ratings. What was the 52-week low for Geron stock?

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are ...Pitney Bowes (PBI 6.72%), Geron (GERN 6.11%), and Cummins (CMI 2.55%) were among the worst performers on the day. Below, we'll look more closely at these stocks to tell you why they did so poorly ...On top of that, Geron is studying if Imetelstat can also be used for other types of treatment, such as for refractory myelofibrosis or other related disorders. Geron thinks that its Imetelstat sales could reach as much as $3 billion annually by 2030. That’s a huge number for a stock that has a market cap of just $1.3 billion right now.Goldman Sachs Upgrades Geron to Buy From Neutral, Price Target is $4. Sep. 12. MT. Goldman Sachs Initiates Geron at Neutral With $3 Price Target. Mar. 28. MT. Needham Adjusts Price Target on Geron to $4 From $3, Maintains Buy Rating.

Real-Time News, Market Data, and Stock Quotes for Life Science Stocks @ healthstockshub.com Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS - Health Stocks Hub6.0%. 10% most volatile stocks in US Market. 15.3%. 10% least volatile stocks in US Market. 2.9%. Stable Share Price: GERN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week. Volatility Over Time: GERN's weekly volatility (8%) has been stable over the past year.…

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. View Geron Corporation GERN investment & stock informa. Possible cause: Shares of Geron ( GERN -4.48%), a clinical-stage biotech company, were up .